SynthesisReviews in cardiovascular medicine2025
Predictive Value of Red Blood Cell Distribution Width for the Prognosis of Cardiac Arrest: A Systematic Review and Meta-Analysis.
Synthesis in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While a potential relationship between red cell distribution width (RDW) and cardiac arrest (CA) prognosis has been raised, the question of whether there is robust data to support this connection remains open. To examine the association of red blood cell distribution width with prognosis in patients with cardiac arrest. Methods: This study strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Relevant studies were identified from searches conducted in the PubMed, Web of Science, the Cochrane Library, and Embase electronic databases up to March 12, 2025. The Newcastle-Ottawa scale was used to assess the quality of the included studies. The combined effect size was determined utilizing standardized mean differences (SMDs), hazard ratios (HRs), and 95% confidence intervals (CIs). Subgroup analyses were also performed to elucidate the sources of heterogeneity. Simultaneously, we also pooled sensitivity (SEN), specificity (SPE), diagnostic odds ratios (ORs), and the area under the summary receiver operating characteristic curve (AUROC). Results: This meta-analysis encompassed eight studies involving CA patients with CA. Our results suggested that patients who died after CA exhibited higher RDW levels than those who survived (SMD = 0.45; 95% CI: 0.30-0.60). There was a 1.63-fold higher risk of death in CA patients with high RDW levels versus those with low levels (95% CI: 1.27-2.08). The SEN, SPE, and AUC for using the RDW to predict mortality were 0.82 (95% CI: 0.74-0.88), 0.49 (95% CI: 0.23-0.74), and 0.80 (95% CI: 0.76-0.83), respectively. Conclusions: RDW is a relatively accurate predictor of prognosis in patients after CA. Thus, using RDW can provide some insights into patient outcomes, enabling healthcare professionals to make informed decisions in advance. The PROSPERO registration: CRD420251023018, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251023018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.